Compare IAC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IAC | EWTX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 1992 | 2021 |
| Metric | IAC | EWTX |
|---|---|---|
| Price | $39.50 | $28.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $45.91 | $34.13 |
| AVG Volume (30 Days) | 759.3K | ★ 1.4M |
| Earning Date | 02-03-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,653,760,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.49 | N/A |
| 52 Week Low | $29.56 | $10.60 |
| 52 Week High | $50.49 | $30.48 |
| Indicator | IAC | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 60.71 |
| Support Level | $38.39 | $25.92 |
| Resistance Level | $40.52 | $28.29 |
| Average True Range (ATR) | 1.02 | 1.59 |
| MACD | -0.16 | 0.38 |
| Stochastic Oscillator | 53.66 | 78.71 |
IAC Inc is comprised of businesses including Angi Inc, Dotdash Meredith and Care.com, among many others ranging from early stage to established businesses. Its Dotdash Meredith segment consists of its Digital and Print businesses. Angi segment offers repairing and remodeling homes to cleaning and landscaping services. Care.com segment is a online destination for families to connect with caregivers for their children, aging parents, pets and homes and for caregivers to connect with families seeking care services. Search segment consists of a collection of websites providing general search services and information, and a Desktop business, which includes business-to-business partnership operations.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.